SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

4.550 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about SciSparc Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Top movers in Monday's pre-market session ↗

March 10, 2025

The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

March 10, 2025

From SciSparc Ltd

Via GlobeNewswire

Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

March 10, 2025

From Clearmind Medicine Inc.

Via GlobeNewswire

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

March 03, 2025

From SciSparc Ltd

Via GlobeNewswire

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax’s Entry into Direct Import of JAC Electric Vehicles

February 27, 2025

From SciSparc Ltd

Via GlobeNewswire

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

February 18, 2025

From SciSparc Ltd

Via GlobeNewswire

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

February 04, 2025

From SciSparc Ltd

Via GlobeNewswire

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

January 15, 2025

From SciSparc Ltd

Via GlobeNewswire

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

January 13, 2025

From SciSparc Ltd

Via GlobeNewswire

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

January 07, 2025

From SciSparc Ltd

Via GlobeNewswire

Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet ↗

January 06, 2025

Via Benzinga

S&P Jumps 1%; Regional Health Properties Shares Spike Higher ↗

January 06, 2025

Via Benzinga

Topics Stocks

Why Is Psychedelic-SciSparc Stock Trading Higher On Monday? ↗

January 06, 2025

SciSparc teams up with Clearmind Medicine on innovative therapies for binge behaviors and secures FDA approval for a Tourette Syndrome Phase 2b trial.

Via Benzinga

US Stocks Open Higher; Dow Jumps Over 200 Points ↗

January 06, 2025

Via Benzinga

Topics Stocks

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

January 06, 2025

From SciSparc Ltd

Via GlobeNewswire

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

December 31, 2024

From SciSparc Ltd

Via GlobeNewswire

S&P 500 Edges Lower, SciSparc Shares Surge ↗

December 26, 2024

Via Benzinga

Topics Stocks

Dow Gains 50 Points, SEALSQ Shares Plummet ↗

December 26, 2024

Via Benzinga

Topics Stocks

Nasdaq Dips Over 100 Points, US Initial Jobless Claims Fall ↗

December 26, 2024

Via Benzinga

SciSparc Shares Skyrocket With AutoMax's First JAC Motors Shipment ↗

December 26, 2024

SciSparc Ltd. shares are soaring after its merger-bound AutoMax Motors received its first shipment of JAC vehicles. The shipment positions AutoMax to begin marketing and sales activities for JAC Motors...

Via Benzinga

Why Zoomcar Shares Are Trading Higher By Around 142%; Here Are 20 Stocks Moving Premarket ↗

December 26, 2024

Via Benzinga

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

December 26, 2024

From SciSparc Ltd

Via GlobeNewswire

SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

December 16, 2024

From SciSparc Ltd

Via GlobeNewswire

Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome ↗

September 30, 2024

SciSparc secures FDA approval for Phase IIb clinical trial of SCI-110, targeting unmet needs in Tourette Syndrome, Global trial begins soon.

Via Benzinga

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment

September 30, 2024

From SciSparc Ltd

Via GlobeNewswire

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

September 26, 2024

From SciSparc Ltd

Via GlobeNewswire

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

September 23, 2024

From SciSparc Ltd

Via GlobeNewswire

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

September 18, 2024

From SciSparc Ltd

Via GlobeNewswire

Clearmind Medicine Files International Patent For Ibogaine Combination Therapy ↗

September 17, 2024

Clearmind Medicine filed an international patent for a treatment that aims to enhance addiction treatment safety and efficacy.

Via Benzinga

Topics Intellectual Property

Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket ↗

September 17, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.